Literature DB >> 14968108

International Campaign for Cures of Spinal Cord Injury Paralysis (ICCP): another step forward for spinal cord injury research.

M Adams1, J F R Cavanagh.   

Abstract

For over 20 years, charitable organizations have worked to promote research that will cure the paralysis associated with spinal cord injury (SCI). When they began this quest, the consequences of SCI were thought to be permanent; that once damaged, the spinal cord could not be repaired. Today, the same organizations are credited with funding research that has realized many significant advances, brought new optimism and changed the outlook of researchers, clinicians and injured individuals alike. Progress in understanding the basic biology of spinal cord repair means that it is now a case of how soon useful treatments will be available, rather than if there will ever be anything to offer. With this in mind, many of the organizations that promote spinal cord research have formed an alliance to determine the ways in which their collaboration can hasten progress. The mission and objectives of this alliance, termed the International Campaign for Cures of Spinal Cord Injury Paralysis (ICCP), are described here.

Entities:  

Mesh:

Year:  2004        PMID: 14968108     DOI: 10.1038/sj.sc.3101597

Source DB:  PubMed          Journal:  Spinal Cord        ISSN: 1362-4393            Impact factor:   2.772


  10 in total

1.  Perseverance is required!

Authors:  Armin Curt
Journal:  Spinal Cord       Date:  2019-04-08       Impact factor: 2.772

Review 2.  Donald Munro Lecture. Spinal cord injury--past, present, and future.

Authors:  William H Donovan
Journal:  J Spinal Cord Med       Date:  2007       Impact factor: 1.985

3.  Deoxyribozymes: new therapeutics to treat central nervous system disorders.

Authors:  Barbara Grimpe
Journal:  Front Mol Neurosci       Date:  2011-09-23       Impact factor: 5.639

Review 4.  Bladder recovery by stem cell based cell therapy in the bladder dysfunction induced by spinal cord injury: systematic review and meta-analysis.

Authors:  Jae Heon Kim; Sung Ryul Shim; Seung Whan Doo; Won Jae Yang; Byung Wook Yoo; Joyce Mary Kim; Young Myoung Ko; Eun Seop Song; Ik Sung Lim; Hong Jun Lee; Yun Seob Song
Journal:  PLoS One       Date:  2015-03-17       Impact factor: 3.240

5.  Nonconvulsive status epilepticus and central paralysis after modified electroconvulsive therapy in a schizophrenic patient.

Authors:  Peng Deng; Xiahong Wang; Jingjing Sui; Jianyue Pang; Qian Liu; Hengfen Li
Journal:  Indian J Psychiatry       Date:  2017 Jul-Sep       Impact factor: 1.759

6.  A Community Perspective on Bowel Management and Quality of Life after Spinal Cord Injury: The Influence of Autonomic Dysreflexia.

Authors:  Jessica A Inskip; Vera-Ellen M Lucci; Maureen S McGrath; Rhonda Willms; Victoria E Claydon
Journal:  J Neurotrauma       Date:  2018-02-09       Impact factor: 5.269

7.  The Functional Role of Spinal Interneurons Following Traumatic Spinal Cord Injury.

Authors:  Mohammad-Masoud Zavvarian; James Hong; Michael G Fehlings
Journal:  Front Cell Neurosci       Date:  2020-05-18       Impact factor: 5.505

8.  Effect of amniotic fluid stem cell transplantation on the recovery of bladder dysfunction in spinal cord-injured rats.

Authors:  Ching-Chung Liang; Sheng-Wen Steven Shaw; Yu-Shien Ko; Yung-Hsin Huang; Tsong-Hai Lee
Journal:  Sci Rep       Date:  2020-06-22       Impact factor: 4.379

Review 9.  Current Concepts of Neural Stem/Progenitor Cell Therapy for Chronic Spinal Cord Injury.

Authors:  Hidenori Suzuki; Yasuaki Imajo; Masahiro Funaba; Norihiro Nishida; Takuya Sakamoto; Takashi Sakai
Journal:  Front Cell Neurosci       Date:  2022-02-03       Impact factor: 5.505

10.  The effects of controlled release of neurotrophin-3 from PCLA scaffolds on the survival and neuronal differentiation of transplanted neural stem cells in a rat spinal cord injury model.

Authors:  Shuo Tang; Xiang Liao; Bo Shi; Yanzhen Qu; Zeyu Huang; Qiang Lin; Xiaodong Guo; Fuxing Pei
Journal:  PLoS One       Date:  2014-09-12       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.